110 related articles for article (PubMed ID: 24623743)
21. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Annicotte JS; Iankova I; Miard S; Fritz V; Sarruf D; Abella A; Berthe ML; Noël D; Pillon A; Iborra F; Dubus P; Maudelonde T; Culine S; Fajas L
Mol Cell Biol; 2006 Oct; 26(20):7561-74. PubMed ID: 17015477
[TBL] [Abstract][Full Text] [Related]
22. Activation of testicular orphan receptor 4 by fatty acids.
Tsai NP; Huq M; Gupta P; Yamamoto K; Kagechika H; Wei LN
Biochim Biophys Acta; 2009; 1789(11-12):734-40. PubMed ID: 19800043
[TBL] [Abstract][Full Text] [Related]
23. [Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy].
Annicotte JS; Culine S; Fajas L
Bull Cancer; 2007 Feb; 94(2):135-7. PubMed ID: 17337382
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
Luconi M; Cantini G; Serio M
Steroids; 2010; 75(8-9):585-94. PubMed ID: 19900469
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in the study of testicular nuclear receptor 4.
Ding XF; Yu SC; Chen BD; Lin SJ; Chang C; Li GH
J Zhejiang Univ Sci B; 2013 Mar; 14(3):171-7. PubMed ID: 23463759
[TBL] [Abstract][Full Text] [Related]
26. PPARγ-independent thiazolidinedione-mediated inhibition of NUR77 expression in vascular endothelial cells.
Hu Y; Liu HB; Simpson RW; Dear AE
J Endocrinol; 2011 Jan; 208(1):R1-7. PubMed ID: 20978184
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist.
Bajare S; Anthony J; Nair A; Marita R; Damre A; Patel D; Rao C; Sivaramakrishnan H; Deka N
Eur J Med Chem; 2012 Dec; 58():355-60. PubMed ID: 23142675
[TBL] [Abstract][Full Text] [Related]
28. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
29. TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation.
Xie S; Lee YF; Kim E; Chen LM; Ni J; Fang LY; Liu S; Lin SJ; Abe J; Berk B; Ho FM; Chang C
Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13353-8. PubMed ID: 19666541
[TBL] [Abstract][Full Text] [Related]
30. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
31. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.
Galli A; Ceni E; Mello T; Polvani S; Tarocchi M; Buccoliero F; Lisi F; Cioni L; Ottanelli B; Foresta V; Mastrobuoni G; Moneti G; Pieraccini G; Surrenti C; Milani S
Hepatology; 2010 Aug; 52(2):493-505. PubMed ID: 20683949
[TBL] [Abstract][Full Text] [Related]
32. TR4 activates FATP1 gene expression to promote lipid accumulation in 3T3-L1 adipocytes.
Choi H; Kim SJ; Park SS; Chang C; Kim E
FEBS Lett; 2011 Sep; 585(17):2763-7. PubMed ID: 21843524
[TBL] [Abstract][Full Text] [Related]
33. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Cheung KF; Zhao J; Hao Y; Li X; Lowe AW; Cheng AS; Sung JJ; Yu J
Cancer; 2013 Mar; 119(6):1217-26. PubMed ID: 23212831
[TBL] [Abstract][Full Text] [Related]
34. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.
Subbarayan V; Sabichi AL; Kim J; Llansa N; Logothetis CJ; Lippman SM; Menter DG
Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1710-6. PubMed ID: 15533897
[TBL] [Abstract][Full Text] [Related]
35. The role of peroxisome proliferator-activated receptor gamma in prostate cancer.
Elix C; Pal SK; Jones JO
Asian J Androl; 2018; 20(3):238-243. PubMed ID: 28597850
[TBL] [Abstract][Full Text] [Related]
36. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells.
Ogawa D; Nomiyama T; Nakamachi T; Heywood EB; Stone JF; Berger JP; Law RE; Bruemmer D
Circ Res; 2006 Apr; 98(7):e50-9. PubMed ID: 16556873
[TBL] [Abstract][Full Text] [Related]
37. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.
Ondrey F
Clin Cancer Res; 2009 Jan; 15(1):2-8. PubMed ID: 19118026
[TBL] [Abstract][Full Text] [Related]
40. False responses of Renilla luciferase reporter control to nuclear receptor TR4.
Zhang D; Atlasi SS; Patel KK; Zhuang Z; Heaney AP
Mol Cell Biochem; 2017 Jun; 430(1-2):139-147. PubMed ID: 28210900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
